Exicure to present Phase 2 trial data on burixafor for multiple myeloma treatment.
ByAinvest
Wednesday, Jan 21, 2026 7:04 am ET1min read
XCUR--
Exicure will present a poster at the 2026 Tandem Meetings, highlighting results from its Phase 2 trial evaluating burixafor in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT). The trial assessed burixafor's ability to mobilize hematopoietic progenitor cells by blocking CXCR4, a chemokine receptor that plays a central role in cell migration. Exicure previously shared positive topline data from the trial.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet